Prot #NU 13S02: Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/28/14 → 11/14/24

Funding

  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #NU 13S02)